Skip to main content
drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Virus-like particle–drug conjugate (bel-sar; AU-011) linked to an IRDye 700DX photosensitizer that selectively binds heparan sulfate proteoglycans on tumor cells; activation by near-infrared laser triggers localized photochemical membrane damage causing rapid necrotic and immunogenic cell death.
nci_thesaurus_concept_id
C137951
nci_thesaurus_preferred_term
Belzupacap Sarotalocan
nci_thesaurus_definition
A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.
drug_mesh_term
Photosensitizing Agents
drug_category
PEPTIDE DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Suprachoroidal
drug_mechanism_of_action
Virus-like particle–photosensitizer conjugate that binds heparan sulfate proteoglycans on tumor cells; activation by near‑infrared light triggers IRDye 700DX to generate reactive oxygen species and induce localized photochemical membrane damage, leading to rapid necrotic and immunogenic cell death while sparing surrounding healthy tissue.
drug_name
Belzupacap sarotalocan
nct_id_drug_ref
NCT06007690